{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:23:40Z","timestamp":1778217820315,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T00:00:00Z","timestamp":1454976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/leu.2016.20","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T14:40:23Z","timestamp":1455115223000},"page":"1255-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV"],"prefix":"10.1038","volume":"30","author":[{"given":"M B","family":"Miranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lauseker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-P","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Proetel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hanfstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"Baerlocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D K","family":"Hossfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-J","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S W","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T H","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Pr\u00fcmmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Neben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Mahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Pl\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Flasshove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Rendenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-K","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,9]]},"reference":[{"key":"BFleu201620_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553\u2013561.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201620_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu201620_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015; 126: 42\u201349.","journal-title":"Blood"},{"key":"BFleu201620_CR6","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","volume":"29","author":"AJ Swerdlow","year":"2011","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29: 4096\u20134104.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","volume":"100","author":"AK Ng","year":"2002","unstructured":"Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989\u20131996.","journal-title":"Blood"},{"key":"BFleu201620_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","volume":"27","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S et al. Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol 2009; 27: 904\u2013910.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/bjc.2011.313","volume":"105","author":"JA Royle","year":"2011","unstructured":"Royle JA, Baade PD, Joske D, Girschik J, Fritschi L . Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011; 105: 1076\u20131081.","journal-title":"Br J Cancer"},{"key":"BFleu201620_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","volume":"85","author":"C Dong","year":"2001","unstructured":"Dong C, Hemminki K . Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001; 85: 997\u20131005.","journal-title":"Br J Cancer"},{"key":"BFleu201620_CR11","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224\u20132232.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1179\/102453308X316022","volume":"13","author":"F Radaelli","year":"2008","unstructured":"Radaelli F, Onida F, Rossi FG, Zilioli VR, Colombi M, Usardi P et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology 2008; 13: 195\u2013202.","journal-title":"Hematology"},{"key":"BFleu201620_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T . Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577\u2013583.","journal-title":"Br J Haematol"},{"key":"BFleu201620_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","volume":"19","author":"S Bhatia","year":"2001","unstructured":"Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464\u2013471.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR15","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1200\/JCO.1994.12.10.2187","volume":"12","author":"R Lowsky","year":"1994","unstructured":"Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187\u20132192.","journal-title":"J Clin Oncol"},{"key":"BFleu201620_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/1097-0142(19900201)65:3<473::AID-CNCR2820650316>3.0.CO;2-V","volume":"65","author":"M Lishner","year":"1990","unstructured":"Lishner M, Patterson B, Kandel R, Fyles G, Curtis JE, Meharchand J et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990; 65: 473\u2013476.","journal-title":"Cancer"},{"key":"BFleu201620_CR17","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992\u20135001.","journal-title":"Blood"},{"key":"BFleu201620_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","volume":"117","author":"NS Majhail","year":"2011","unstructured":"Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316\u2013322.","journal-title":"Blood"},{"key":"BFleu201620_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.radonc.2011.09.013","volume":"105","author":"D Bartkowiak","year":"2012","unstructured":"Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B et al. Second cancer after radiotherapy, 1981\u20132007. Radiother Oncol 2012; 105: 122\u2013126.","journal-title":"Radiother Oncol"},{"key":"BFleu201620_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rpd\/ncr166","volume":"146","author":"K Doi","year":"2011","unstructured":"Doi K, Mieno MN, Shimada Y, Yonehara H, Yoshinaga S . Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors. Radiat Prot Dosimetry 2011; 146: 263\u2013267.","journal-title":"Radiat Prot Dosimetry"},{"key":"BFleu201620_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"AE Grulich","year":"2007","unstructured":"Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM . Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59\u201367.","journal-title":"Lancet"},{"key":"BFleu201620_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/387450a0","volume":"387","author":"L Brown","year":"1997","unstructured":"Brown L, McCarthy N . DNA repair. A sense-abl response? Nature 1997; 387: 450\u2013451.","journal-title":"Nature"},{"key":"BFleu201620_CR23","unstructured":"Glivec - Summary of product characteristics 2011; [cited October 2012]; Available from: \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000406\/WC500022207.pdf\n                    \n                  ."},{"key":"BFleu201620_CR24","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"S Appel","year":"2005","unstructured":"Appel S, Balabanov S, Brummendorf TH, Brossart P . Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005; 23: 1082\u20131088.","journal-title":"Stem Cells"},{"key":"BFleu201620_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","volume":"19","author":"L Roy","year":"2005","unstructured":"Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F . Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005; 19: 1689\u20131692.","journal-title":"Leukemia"},{"key":"BFleu201620_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/sj.leu.2404025","volume":"20","author":"PR Pilot","year":"2006","unstructured":"Pilot PR, Sablinska K, Owen S, Hatfield A . Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006; 20: 148 author reply 149.","journal-title":"Leukemia"},{"key":"BFleu201620_CR27","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","volume":"118","author":"D Verma","year":"2011","unstructured":"Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011; 118: 4353\u20134358.","journal-title":"Blood"},{"key":"BFleu201620_CR28","doi-asserted-by":"publisher","first-page":"e2015003","DOI":"10.4084\/mjhid.2015.003","volume":"7","author":"G Helbig","year":"2015","unstructured":"Helbig G, Bober G, Seweryn M, Wichary R, Tukiendorf A, Sedlak L et al. Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience. Mediterr J Hematol Infect Dis 2015; 7: e2015003.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"BFleu201620_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12288-013-0328-2","volume":"30","author":"BK Shah","year":"2014","unstructured":"Shah BK, Ghimire KB . Second primary malignancies in chronic myeloid leukemia. Indian J Hematol Blood Transfus 2014; 30: 236\u2013240.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"BFleu201620_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 2015; 169: 683\u2013688.","journal-title":"Br J Haematol"},{"key":"BFleu201620_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4149\/neo_2011_03_256","volume":"58","author":"J Voglova","year":"2011","unstructured":"Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58: 256\u2013262.","journal-title":"Neoplasma"},{"key":"BFleu201620_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","volume":"94","author":"A Fabarius","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015; 94: 2015\u20132024.","journal-title":"Ann Hematol"},{"key":"BFleu201620_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/aje\/kwq262","volume":"172","author":"P Rebora","year":"2010","unstructured":"Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG . Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 2010; 172: 1028\u20131033.","journal-title":"Am J Epidemiol"},{"issue":"25","key":"BFleu201620_CR34","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","volume":"118","author":"H. Frederiksen","year":"2011","unstructured":"Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT . Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118: 6515\u20136520.","journal-title":"Blood"},{"key":"BFleu201620_CR35","unstructured":"Esteve J, Benhamou E, Raymond L . Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ 1994, 1\u2013302."},{"key":"BFleu201620_CR36","unstructured":"Robert Koch Institute and the Association of Population-based Cancer Registries in Germany (eds). Cancer in Germany 2007\/2008, 9th edn. Robert Koch Institute: : Berlin, Germany,, 2012. Available from: \n                    http:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Publications\/Cancer_in_Germany\/cancer_chapters_2009_2010\/cancer_germany_2009_2010.pdf?__blob=publicationFile\n                    \n                  ."},{"key":"BFleu201620_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/oxfordjournals.aje.a121617","volume":"99","author":"OS Miettinen","year":"1974","unstructured":"Miettinen OS . Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974; 99: 325\u2013332.","journal-title":"Am J Epidemiol"},{"key":"BFleu201620_CR38","unstructured":"Rothman KJ, Boice HD, Austin H . Epidemiologic Analysis with a Programmable Calculator. Epidemiology Resources, Incorporated 1982; pp 197."},{"key":"BFleu201620_CR39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu201620_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametrical estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFleu201620_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFleu201620_CR42","unstructured":"IARC\/IACR. 2004. International Rules for Multiple Primary Cancers (ICD-0 Third Edition). International Agency for Research on Cancer: Lyon. ISBN. Available from: \n                    http:\/\/www.iacr.com.fr\/MPrules_july2004.pdf\n                    \n                  )."},{"key":"BFleu201620_CR43","unstructured":"R Development Core Team R: A Language and Environment for Statistical Computing. The R Foundation for Statistical Computing: Vienna, Austria, 2011."},{"key":"BFleu201620_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu201620_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123\u20131132.","journal-title":"Leukemia"},{"key":"BFleu201620_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/leu.2015.258","volume":"30","author":"T Radivoyevitch","year":"2015","unstructured":"Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia 2015; 30: 285\u2013294.","journal-title":"Leukemia"},{"key":"BFleu201620_CR47","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.leukres.2009.01.042","volume":"33","author":"H Brenner","year":"2009","unstructured":"Brenner H, Gondos A, Pulte D . Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leuk Res 2009; 33: 1604\u20131608.","journal-title":"Leuk Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201620","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201620.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:05:43Z","timestamp":1684433143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,9]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFleu201620"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.20","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,9]]},"assertion":[{"value":"22 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BH has received honoraria from Bristol-Myers Squibb (BMS) and research funding from Novartis; SWK honoraria and research funding by Novartis; MCM honoraria and research funding from Novartis, BMS, ARIAD and Pfizer; MP honoraria from BMS and consultancy from Novartis; AH honoraria from Novartis, BMS, ARIAD, consultancy from Novartis and research funding from Novartis, ARIAD and Pfizer; RH research funding from Novartis and BMS and SS honoraria from Novartis, BMS, Pfizer, ARIAD and research funding from Novartis and BMS. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}